probenecid has been researched along with Chronic Kidney Diseases in 12 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Allopurinol can be used for the prophylactic management of chronic hyperuricemia in patients with CKD, but the recommended decreased dosage may limit efficacy and serious hypersensitivity reactions may preclude its use." | 4.88 | Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. ( Curiel, RV; Guzman, NJ, 2012) |
| "Although the clinical implication of hyperuricemia in chronic kidney disease has been an issue of active debate, recent data suggested a causative role of uric acid (UA) in the development of renal disease." | 3.88 | Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( Kang, DH, 2018) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| "Probenecid PBPK model was adapted from the Simcyp database and re-verified to capture its dose-dependent pharmacokinetics (n = 9 studies)." | 1.91 | Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease. ( Galetin, A; Rostami-Hodjegan, A; Scotcher, D; Shen, H; Snoeys, J; Tan, SPF; Willemin, ME, 2023) |
| "Gout has significant impact on the quality of life with over-utilisation of health resources." | 1.56 | Burden and management of gout in a multi-ethnic Asian cohort. ( Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG, 2020) |
| "His uric acid was 11 mg/dL despite maximal dosing of febuxostat." | 1.48 | Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. ( Case, R; Jester, G; Wentworth, B, 2018) |
| "Hyperuricemia is an independent risk factor for progression of kidney disease." | 1.48 | Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease. ( Cheetham, TC; Levy, G; Rashid, N; Shi, JM, 2018) |
| "CKD mice exhibited marked left ventricular hypertrophy and myocardial fibrosis, which were reversed by treatment with the CB1R antagonist." | 1.42 | CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia. ( Chen, Y; Hsu, SC; Hsu, YJ; Huang, SM; Lee, HS; Lin, CY; Lin, SH; Shih, CC; Tsai, CS, 2015) |
| "Patients with gout have comorbidities, but the impact of these comorbidities on treatment has not been studied." | 1.37 | Prevalence of contraindications and prescription of pharmacologic therapies for gout. ( Crittenden, DB; Fisher, MC; Goldfarb, DS; Keenan, RT; Krasnokutsky, S; Lee, KH; O'Brien, WR; Oh, C; Pillinger, MH, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Liu, J | 1 |
| Ma, L | 1 |
| Fu, P | 1 |
| Tan, SPF | 1 |
| Willemin, ME | 1 |
| Snoeys, J | 1 |
| Shen, H | 1 |
| Rostami-Hodjegan, A | 1 |
| Scotcher, D | 1 |
| Galetin, A | 1 |
| Chua, CKT | 1 |
| Cheung, PP | 1 |
| Santosa, A | 1 |
| Lim, AYN | 1 |
| Teng, GG | 1 |
| Case, R | 1 |
| Wentworth, B | 1 |
| Jester, G | 1 |
| Kang, DH | 1 |
| Levy, G | 1 |
| Shi, JM | 1 |
| Cheetham, TC | 1 |
| Rashid, N | 1 |
| Richette, P | 1 |
| Perez-Ruiz, F | 1 |
| Doherty, M | 1 |
| Jansen, TL | 1 |
| Nuki, G | 1 |
| Pascual, E | 1 |
| Punzi, L | 1 |
| So, AK | 1 |
| Bardin, T | 1 |
| Lin, CY | 1 |
| Hsu, YJ | 1 |
| Hsu, SC | 1 |
| Chen, Y | 1 |
| Lee, HS | 1 |
| Lin, SH | 1 |
| Huang, SM | 1 |
| Tsai, CS | 1 |
| Shih, CC | 1 |
| Stamp, LK | 1 |
| Keenan, RT | 1 |
| O'Brien, WR | 1 |
| Lee, KH | 1 |
| Crittenden, DB | 1 |
| Fisher, MC | 1 |
| Goldfarb, DS | 1 |
| Krasnokutsky, S | 1 |
| Oh, C | 1 |
| Pillinger, MH | 1 |
| Curiel, RV | 1 |
| Guzman, NJ | 1 |
| Watanabe, H | 1 |
| Miyamoto, Y | 1 |
| Honda, D | 1 |
| Tanaka, H | 1 |
| Wu, Q | 1 |
| Endo, M | 1 |
| Noguchi, T | 1 |
| Kadowaki, D | 1 |
| Ishima, Y | 1 |
| Kotani, S | 1 |
| Nakajima, M | 1 |
| Kataoka, K | 1 |
| Kim-Mitsuyama, S | 1 |
| Tanaka, M | 1 |
| Fukagawa, M | 1 |
| Otagiri, M | 1 |
| Maruyama, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| ACTH vs Betamethasone for the Treatment of Acute Gout in Hospitalized Patients: A Randomized, Open Label, Comparative Study[NCT04306653] | 60 participants (Anticipated) | Interventional | 2018-01-05 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for probenecid and Chronic Kidney Diseases
| Article | Year |
|---|---|
Pharmacological urate-lowering approaches in chronic kidney disease.
Topics: Biological Products; Drug Discovery; Flavonoids; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
Improving cardiovascular and renal outcomes in gout: what should we target?
Topics: Allopurinol; Cardiovascular Diseases; Colchicine; Diabetes Mellitus, Type 2; Disease Management; Gou | 2014 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Comorbidity; Con | 2012 |
8 other studies available for probenecid and Chronic Kidney Diseases
| Article | Year |
|---|---|
Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease.
Topics: Biomarkers; Drug Interactions; Humans; Kidney; Models, Biological; Probenecid; Pyridoxic Acid; Renal | 2023 |
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Em | 2020 |
Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Febuxostat; Foot Deformities, Acquired; Gout; Gou | 2018 |
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells.
Topics: Actins; Animals; Antioxidants; Capillaries; Disease Progression; Endothelial Cells; Epithelial-Mesen | 2018 |
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Topics: Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants | 2018 |
CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia.
Topics: Animals; Cannabinoid Receptor Antagonists; Cell Line; Collagen; Drug Evaluation, Preclinical; Fibros | 2015 |
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
Topics: Aged; Aged, 80 and over; Allopurinol; Colchicine; Comorbidity; Contraindications; Diabetes Mellitus; | 2011 |
p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase.
Topics: Animals; Cell Line; Cell Survival; Collagen Type I; Collagen Type I, alpha 1 Chain; Cresols; Cytokin | 2013 |